Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer.
- Janssens, G.O.R.J.
- Rademakers, S.E.
- Terhaard, C.H.J.
- Doornaert, P.A.
- Bijl, H.P.
- Ende, P. van den
- Chin, A.
- Takes, R.P.
- Bree, R. de
- Hoogsteen, I.J.
- Bussink, J.
- Span, P.N.
- Kaanders, J.H.A.M.
DOIAbstract
PURPOSE: Anemia is associated with poor tumor control. It was previously observed that accelerated radiotherapy combined with carbogen breathing and nicotinamide (ARCON) can correct this adverse outcome in patients with head and neck cancer. The purpose of this study was to validate this observation based on data from a randomized trial. EXPERIMENTAL DESIGN: Of 345 patients with cT2-4 laryngeal cancer, 174 were randomly assigned to accelerated radiotherapy and 171 to ARCON. Hemoglobin levels, measured before treatment, were defined as low when <7.5 mmol/L for women and <8.5 mmol/L for men. The hypoxia marker pimonidazole was used to assess the oxygenation status in tumor biopsies. Data were analyzed 2 years after inclusion of the last patie...
Add to ORKG